These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Cancer therapy using bispecific antibodies]. Kadowaki N Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495 [TBL] [Abstract][Full Text] [Related]
27. Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Robertson IB; Mulvaney R; Dieckmann N; Vantellini A; Canestraro M; Amicarella F; O'Dwyer R; Cole DK; Harper S; Dushek O; Kirk P Clin Exp Immunol; 2024 Feb; 215(2):105-119. PubMed ID: 37930865 [TBL] [Abstract][Full Text] [Related]
28. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Yuraszeck T; Kasichayanula S; Benjamin JE Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247 [TBL] [Abstract][Full Text] [Related]
29. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties. Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV MAbs; 2019; 11(2):422-433. PubMed ID: 30550367 [TBL] [Abstract][Full Text] [Related]
30. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Philipp N; Kazerani M; Nicholls A; Vick B; Wulf J; Straub T; Scheurer M; Muth A; Hänel G; Nixdorf D; Sponheimer M; Ohlmeyer M; Lacher SM; Brauchle B; Marcinek A; Rohrbacher L; Leutbecher A; Rejeski K; Weigert O; von Bergwelt-Baildon M; Theurich S; Kischel R; Jeremias I; Bücklein V; Subklewe M Blood; 2022 Sep; 140(10):1104-1118. PubMed ID: 35878001 [TBL] [Abstract][Full Text] [Related]
31. Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed Noguchi Y; Yan M; Tachi T; Yoshimura T J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649281 [No Abstract] [Full Text] [Related]
33. Approaches to implement bispecific antibody treatment of ovarian carcinoma. Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Figini M; Ramakrishna V; Bolis G; Colnaghi MI Cancer Immunol Immunother; 1997; 45(3-4):187-9. PubMed ID: 9435870 [No Abstract] [Full Text] [Related]
34. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244 [TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies in cancer therapy, from the laboratory to the clinic. Koelemij R; Kuppen PJ; van de Velde CJ; Fleuren GJ; Hagenaars M; Eggermont AM J Immunother; 1999 Nov; 22(6):514-24. PubMed ID: 10570750 [TBL] [Abstract][Full Text] [Related]
36. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies. Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461 [TBL] [Abstract][Full Text] [Related]
37. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Metz S; Haas AK; Daub K; Croasdale R; Stracke J; Lau W; Georges G; Josel HP; Dziadek S; Hopfner KP; Lammens A; Scheuer W; Hoffmann E; Mundigl O; Brinkmann U Proc Natl Acad Sci U S A; 2011 May; 108(20):8194-9. PubMed ID: 21536919 [TBL] [Abstract][Full Text] [Related]
38. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Waite JC; Wang B; Haber L; Hermann A; Ullman E; Ye X; Dudgeon D; Slim R; Ajithdoss DK; Godin SJ; Ramos I; Wu Q; Oswald E; Poon P; Golubov J; Grote D; Stella J; Pawashe A; Finney J; Herlihy E; Ahmed H; Kamat V; Dorvilliers A; Navarro E; Xiao J; Kim J; Yang SN; Warsaw J; Lett C; Canova L; Schulenburg T; Foster R; Krueger P; Garnova E; Rafique A; Babb R; Chen G; Stokes Oristian N; Siao CJ; Daly C; Gurer C; Martin J; Macdonald L; MacDonald D; Poueymirou W; Smith E; Lowy I; Thurston G; Olson W; Lin JC; Sleeman MA; Yancopoulos GD; Murphy AJ; Skokos D Sci Transl Med; 2020 Jun; 12(549):. PubMed ID: 32581132 [TBL] [Abstract][Full Text] [Related]